Trisenox® in Women With Metastatic Endometrial Cancer

Summary

The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide (Trisenox®) as judged by shrinkage of their tumor.

Timeline

Start

2010-03

Primary completion

2012-03

Completion

2012-03

Outcome

Outcome not reported

Stopped (Enrollment): “Accrual was very low. No subject had been enrolled in a year.”

Drugs

Indications